Our media and press kit contains the information you need to share stories of discovery and communicate science to the public in a timely fashion.

Our Mission

To comprehensively and systematically characterize mechanisms of action underlying infectious, metabolic and immune-mediated diseases; the NIMML will translate this new knowledge towards developing innovative therapeutics for human diseases that are safer and more effective.

Our Vision

To become a world leading research laboratory in translational, personalized, predictive, participatory, and preventive medicine.

Our Values

Integrity, creativity, efficiency, teamwork, confidentiality, customer-service orientation, loyalty, commitment, trust, attention to detail, and impeccable work ethics.

About NIMML

The NIMML uses innovation to tackle challenges in infectious, immune-mediated and chronic inflammatory disease research. We combine computational approaches with pre-clinical and clinical experimentation to transition new biological knowledge into safer and more effective medicines for human diseases.

NIMML History

The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) is a research organization founded in 2002 under the guidance of Dr. Bassaganya-Riera and Dr. Hontecillas. NIMML is committed to a transdisciplinary, team-science approach with a personalized medicine focus at the interface of immunology, inflammation and nutrition. The NIMML research programs incorporate drug development, nutritional immunology, computational immunology, and translational research in immune mediated, infectious and chronic inflammatory diseases.

The NIMML research has pioneered pipelines applying high-throughput computational and experimental immunology techniques and system biology approaches in translational immunology research and discovery. Through the Center for Modeling Immunity to Enteric Pathogens Program, we have applied high performance computing techniques to model and simulate human immunology systems and help immunologists conduct in silico experiments in order to develop a more mechanistic experimental design, validate hypotheses and save significant time and laboratory cost.

NIMML research has received support from the National Institute of Allergy and Infectious Disease at the National Institutes of Health, the National Center for Complementary and Alternative Medicine, Bristol Myers Squibb, Lipid Nutrition, Cognis Nutrition and Health GmbH, BASF, USDA, and commodity groups with a growing research funding portfolio exceeding $15 million.

​1. Focus: NIMML’s research areas include drug development, nutritional immunology, immune mediated disease, infectious disease, chronic diseases, and computational immunology

2. Team: NIMML is composed of over 30 active lab members trained in immunology, biochemistry, microbiology, engineering, bioinformatics, computer science, mathematics, and physics

3. Portfolio: NIMML has a growing research funding portfolio exceeding $15 million, with over 100 publications, and 20 patents and applications

4. MIEP: NIMML’s houses the Center for Modeling Immunity to Enteric Pathogens (MIEP) one of four NIAID-funded centers in Modeling Immunity for Biodefense (MIB)

5. Unique Style: NIMML integrates computational modeling with experimental approaches to develop innovative therapeutics for human diseases

1. Developing powerful tools to quantitatively understand the dynamics of complex immunological systems

2. Identifying and validating novel therapeutic targets for infectious, immune mediated and chronic inflammatory/metabolic diseases- examples include: type two diabetes (T2D), Helicobacter pylori, inflammatory bowel disease (IBD)

3. Discovering how diet and nutritional factors influence the immune responses, thereby regulating health and disease outcomes

4. Conducting translational research integrating computational modeling with novel experimental approaches

5. Enabling students to excel in translational research and reach their career goals in environments such as Amazon, QIAGEN, University of California Berkley, Feinstein

6. Creating innovative pipelines for drug development to identify and test the efficacy and safety of new compounds by applying molecular and systems modeling, testing the mechanism of action in animal models of disease, and conducting human clinical trials to validate the results of animal models